Routy, Bertrand

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 5,671

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 3,488

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 908

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 897

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Derosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 685

Anticancer effects of the microbiome and its products

Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology

Gut microbiota and healthBacterial Cancer Therapy

Cited by 538

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 526

The gut microbiota influences anticancer immunosurveillance and general health

Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 523

Microbiome and Anticancer Immunosurveillance

Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 478

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., et al. (2021) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 437

Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

Derosa, L., Routy, B., Fidelle, M., Iebba, V., Alla, L., Pasolli, E., Segata, N., Desnoyer, A., Pietrantonio, F., Ferrere, G., et al. (2020) · European Urology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 398

Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 396

Moving towards personalized treatments of immune-related adverse events

Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 351

The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer

Hakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., et al. (2020) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 316

A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota

Messaoudene, M., Pidgeon, R., Richard, C., Ponce, M., Diop, K., Benlaifaoui, M., Nolin-Lapalme, A., Cauchois, F., Malo, J., Belkaid, W., et al. (2022) · Cancer Discovery

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 250

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 246

A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers

Fidelle, M., Rauber, C., Alves Costa Silva, C., Tian, A.-L., Lahmar, I., de La Varende, A.-L. M., Zhao, L., Thelemaque, C., Lebhar, I., Messaoudene, M., et al. (2023) · Science

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 243

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors

Elkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 208

Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer

Roberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 208

Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 198

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy

Fumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., et al. (2018) · British Journal of Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Research Studies

Cited by 176

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies

Oster, P., Vaillant, L., Riva, E., McMillan, B., Begka, C., Truntzer, C., Richard, C., Leblond, M. M., Messaoudene, M., Machremi, E., et al. (2022) · Gut

Cancer Immunotherapy and BiomarkersHelicobacter pylori-related gastroenterology studies

Cited by 176

Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., Kroemer, G., Fidelle, M., Christodoulidis, S., Segata, N., Thomas, A. M., et al. (2021) · Cell Death & Differentiation

Gut microbiota and healthCancer, Lipids, and Metabolism

Cited by 172